Merck posts quarterly loss due to Cidara charge, sales rise 5%

Merck & Co. reported a first-quarter loss after an acquisition-related charge outweighed a 5% increase in product sales. The sales growth was driven by cancer and respiratory drugs, indicating underlying operating strength despite the one-time hit. The result is a modestly negative earnings headline, but the market impact should be limited absent further detail on the charge or guidance.

Analysis

Merck & Co. reported a first-quarter loss after an acquisition-related charge outweighed a 5% increase in product sales. The sales growth was driven by cancer and respiratory drugs, indicating underlying operating strength despite the one-time hit. The result is a modestly negative earnings headline, but the market impact should be limited absent further detail on the charge or guidance.